<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
  <title>Dr Mariam - Fast Exam (253 Qs)</title>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@500;600;700&display=swap" rel="stylesheet">
  <script src="https://cdn.tailwindcss.com"></script>
  <style>
    body { font-family: 'Inter', sans-serif; }
    .option-btn {
      transition: background-color 0.1s, border-color 0.1s;
    }
    .option-btn:hover {
      background-color: #eef2ff !important;
      border-color: #6366f1 !important;
    }
  </style>
</head>
<body class="bg-gradient-to-br from-blue-50 to-indigo-100 text-gray-800 min-h-screen flex items-center justify-center p-4">
  <div id="app-container" class="w-full max-w-2xl mx-auto">
    <!-- Exam Card -->
    <div id="exam-card" class="bg-white p-6 sm:p-8 rounded-2xl shadow-2xl">
      <div class="flex justify-between items-center mb-6 border-b border-gray-200 pb-4">
        <h1 class="text-xl sm:text-2xl font-bold text-indigo-700 flex items-center">
          <span class="mr-2">Dr Mariam</span>
        </h1>
        <div class="flex space-x-4">
          <div id="progress-text" class="text-sm font-medium text-gray-600">Question 1 of 253</div>
          <div id="score-text" class="text-sm font-medium text-indigo-600">Score: 0</div>
        </div>
      </div>
      <div id="question-area">
        <p id="question-text" class="text-lg sm:text-xl font-semibold mb-6 min-h-[6rem] flex items-center"></p>
        <div id="options-container" class="space-y-3"></div>
      </div>
      <div class="flex justify-between items-center mt-8 pt-6 border-t border-gray-200">
        <button id="prev-btn" class="bg-gray-200 text-gray-700 px-6 py-2 rounded-lg font-medium hover:bg-gray-300 disabled:opacity-50 disabled:cursor-not-allowed">
          Previous
        </button>
        <button id="next-btn" class="bg-indigo-600 text-white px-6 py-2 rounded-lg font-medium hover:bg-indigo-700 disabled:opacity-50 disabled:cursor-not-allowed shadow-lg">
          Next
        </button>
      </div>
    </div>

    <!-- Results Card -->
    <div id="results-card" class="bg-white p-8 rounded-2xl shadow-2xl text-center hidden">
      <h2 class="text-3xl font-bold text-indigo-700 mb-2">Exam Complete!</h2>
      <p class="text-lg text-gray-600 mb-6">Great job!</p>
      <p class="text-xl text-gray-700 mb-2">Final Score:</p>
      <p id="final-score" class="text-5xl font-extrabold text-indigo-700 mb-8">0 / 253</p>
      <button id="restart-btn" class="bg-indigo-600 text-white px-10 py-3 rounded-lg font-medium hover:bg-indigo-700 text-lg">
        Restart
      </button>
      <div id="answer-key" class="mt-10 text-left max-h-[40vh] overflow-y-auto">
        <h3 class="text-xl font-bold mb-4 text-center text-indigo-700">Answer Key</h3>
        <div id="answer-key-content" class="space-y-3 text-sm"></div>
      </div>
    </div>
  </div>

  <script>
    // ==================== 253 FAST-LOADED QUESTIONS FROM YOUR SLIDES ====================
const questions = [
  // SECTION 1: Gastrointestinal Infections & Enterotoxigenic Poisonings (40 questions)
  {
    question: "Which pathogens cause watery diarrhea via toxin-mediated mechanisms?",
    options: ["Shigella, Salmonella", "ETEC, Rotavirus, Norovirus", "Campylobacter, EHEC", "Vibrio cholerae only"],
    answer: "ETEC, Rotavirus, Norovirus"
  },
  {
    question: "Dysentery (bloody diarrhea) is primarily caused by which type of pathogen action?",
    options: ["Toxin-mediated", "Mucosal invasion", "Neurotoxin", "Cytokine storm"],
    answer: "Mucosal invasion"
  },
  {
    question: "Which pathogens are associated with dysentery?",
    options: ["ETEC, Norovirus", "Shigella, Salmonella, Campylobacter, EHEC", "Rotavirus, Adenovirus", "Vibrio, Giardia"],
    answer: "Shigella, Salmonella, Campylobacter, EHEC"
  },
  {
    question: "What is the first-line treatment for mild-moderate dehydration in GI infections?",
    options: ["IV fluids", "Oral rehydration therapy (ORT)", "Antibiotics", "Antidiarrheals"],
    answer: "Oral rehydration therapy (ORT)"
  },
  {
    question: "In severe dehydration, what is given initially before switching to ORT when stable?",
    options: ["D5W", "IV Lactated Ringer’s", "Normal saline only", "Colloid solution"],
    answer: "IV Lactated Ringer’s"
  },
  {
    question: "Which fluids should be avoided as adjunct therapy in dehydration?",
    options: ["Water, ORS", "Soft drinks, sports drinks, sweet juices", "IV crystalloids", "Pedialyte"],
    answer: "Soft drinks, sports drinks, sweet juices"
  },
  {
    question: "For ETEC in children (traveler's diarrhea-type), what is the antibiotic of choice?",
    options: ["Ciprofloxacin 750 mg x 3 days", "Azithromycin 10 mg/kg/day x 3 days", "Ceftriaxone 50 mg/kg/day", "Metronidazole 500 mg"],
    answer: "Azithromycin 10 mg/kg/day x 3 days"
  },
  {
    question: "For ETEC in adults, what is the preferred fluoroquinolone regimen?",
    options: ["Ciprofloxacin 500 mg bid x 5 days", "Ciprofloxacin 750 mg PO daily x 1–3 days", "Levofloxacin 250 mg x 7 days", "Ofloxacin 400 mg x 3 days"],
    answer: "Ciprofloxacin 750 mg PO daily x 1–3 days"
  },
  {
    question: "Alternative to fluoroquinolone for ETEC in adults includes:",
    options: ["Doxycycline", "Alt: rifaximin or azithromycin", "Erythromycin", "Clindamycin"],
    answer: "Alt: rifaximin or azithromycin"
  },
  {
    question: "For Campylobacter in children, what is the preferred macrolide?",
    options: ["Erythromycin 30 mg/kg/day x 3–5 days", "Azithromycin 10 mg/kg/day x 3 days", "Clarithromycin 15 mg/kg", "Roxithromycin"],
    answer: "Azithromycin 10 mg/kg/day x 3 days"
  },
  {
    question: "For Campylobacter in adults in FQ-resistant areas, what is used?",
    options: ["Ciprofloxacin 750 mg x 7 days", "Azithromycin 500 mg PO daily x 3 days", "Doxycycline 100 mg bid", "Ceftriaxone IM"],
    answer: "Azithromycin 500 mg PO daily x 3 days"
  },
  {
    question: "Alternative to azithromycin for Campylobacter in adults?",
    options: ["Metronidazole", "Alt: ciprofloxacin 750 mg x 7 days", "Vancomycin", "Penicillin"],
    answer: "Alt: ciprofloxacin 750 mg x 7 days"
  },
  {
    question: "For non-typhoidal Salmonella in children with systemic or high-risk features, what IV therapy is used?",
    options: ["Azithromycin 10 mg/kg/day x 7 days", "Ceftriaxone 100 mg/kg/day IV q12h x 7–10 days or Azithromycin 20 mg/kg/day x 7 days", "Cipro 400 mg IV", "Ampicillin"],
    answer: "Ceftriaxone 100 mg/kg/day IV q12h x 7–10 days or Azithromycin 20 mg/kg/day x 7 days"
  },
  {
    question: "For non-typhoidal Salmonella in adults with high-risk features, what is preferred?",
    options: ["Ceftriaxone 2 g IV/IM once or Ciprofloxacin 750 mg PO x 7–10 days", "Azithromycin 500 mg x 3 days", "Doxycycline", "TMP-SMX"],
    answer: "Ceftriaxone 2 g IV/IM once or Ciprofloxacin 750 mg PO x 7–10 days"
  },
  {
    question: "For Shigella in children, what is the antibiotic of choice?",
    options: ["Ciprofloxacin", "Azithromycin 10 mg/kg/day x 3 days or Ceftriaxone 50 mg/kg/day x 3 days", "Metronidazole", "Erythromycin"],
    answer: "Azithromycin 10 mg/kg/day x 3 days or Ceftriaxone 50 mg/kg/day x 3 days"
  },
  {
    question: "For Shigella in adults, what is the preferred regimen?",
    options: ["Azithromycin 500 mg x 3 days or Ceftriaxone 2 g x 1 dose", "Ciprofloxacin 500 mg bid", "Doxycycline", "Clindamycin"],
    answer: "Azithromycin 500 mg x 3 days or Ceftriaxone 2 g x 1 dose"
  },
  {
    question: "In Shigella treatment, what drug class should be avoided?",
    options: ["Macrolides", "Antimotility drugs", "Cephalosporins", "Fluoroquinolones"],
    answer: "Antimotility drugs"
  },
  {
    question: "Which vaccine is available for typhoid prevention?",
    options: ["Vivotif (Ty21a oral)", "VIPS IM or Ty21a oral", "RotaTeq only", "Vaxchora only"],
    answer: "VIPS IM or Ty21a oral"
  },
  {
    question: "Which vaccine is given to infants for rotavirus prevention?",
    options: ["Typhoid vaccine", "RotaTeq or Rotarix", "Cholera vaccine", "Hepatitis A"],
    answer: "RotaTeq or Rotarix"
  },
  {
    question: "Which vaccine is used for cholera prevention in travelers?",
    options: ["Ty21a", "Vaxchora", "RotaTeq", "Gardasil"],
    answer: "Vaxchora"
  },
  {
    question: "Prevention of GI infections includes hygiene and:",
    options: ["Eating raw food", "Safe food preparation", "Drinking tap water", "Sharing utensils"],
    answer: "Safe food preparation"
  },
  {
    question: "Which is NOT a recommended prevention strategy for GI infections?",
    options: ["Hand hygiene", "Safe food prep", "Drinking unboiled water in endemic areas", "Vaccination"],
    answer: "Drinking unboiled water in endemic areas"
  },
  {
    question: "What is the leading cause of morbidity and mortality in children under 5 worldwide?",
    options: ["Malaria", "Diarrheal diseases", "Pneumonia", "Measles"],
    answer: "Diarrheal diseases"
  },
  {
    question: "Acute diarrhea is defined as lasting:",
    options: ["<7 days", ">30 days", "7–13 days", "14–29 days"],
    answer: "<7 days"
  },
  {
    question: "Persistent diarrhea lasts:",
    options: ["<7 days", "7–13 days", "14–29 days", ">30 days"],
    answer: "14–29 days"
  },
  {
    question: "Chronic diarrhea is defined as lasting:",
    options: ["<14 days", "14–29 days", ">30 days", "7–13 days"],
    answer: ">30 days"
  },
  {
    question: "Diagnosis of dysentery is supported by:",
    options: ["Stool cultures and fecal PCRs", "Blood culture only", "Urine analysis", "Chest X-ray"],
    answer: "Stool cultures and fecal PCRs"
  },
  {
    question: "Rehydration therapy is central in:",
    options: ["Antibiotic failure", "Oral rehydration therapy (ORT) for mild/moderate cases", "IV antibiotics", "Surgery"],
    answer: "Oral rehydration therapy (ORT) for mild/moderate cases"
  },
  {
    question: "IV fluids are indicated in:",
    options: ["Mild cases", "Severe dehydration", "Asymptomatic", "Chronic diarrhea"],
    answer: "Severe dehydration"
  },
  {
    question: "Antibiotics are used in GI infections for:",
    options: ["All cases", "Shigella, Salmonella, Campylobacter, EHEC, invasive", "Viral only", "Prophylaxis"],
    answer: "Shigella, Salmonella, Campylobacter, EHEC, invasive"
  },
  {
    question: "Antidiarrheals are contraindicated in:",
    options: ["Viral diarrhea", "Invasive/bloody diarrhea", "Mild cases", "Children only"],
    answer: "Invasive/bloody diarrhea"
  },
  {
    question: "Prevention includes personal hygiene and:",
    options: ["Vaccination", "Typhoid, rotavirus, cholera vaccines", "Antibiotics", "Probiotics"],
    answer: "Typhoid, rotavirus, cholera vaccines"
  },
  {
    question: "Which is NOT a cause of watery diarrhea?",
    options: ["ETEC", "Shigella", "Norovirus", "Rotavirus"],
    answer: "Shigella"
  },
  {
    question: "Which is NOT a cause of dysentery?",
    options: ["ETEC", "EHEC", "Campylobacter", "Salmonella"],
    answer: "ETEC"
  },
  {
    question: "ORT contains:",
    options: ["Glucose + sodium", "Glucose + electrolytes", "Sucrose only", "Water only"],
    answer: "Glucose + electrolytes"
  },
  {
    question: "Severe dehydration signs include:",
    options: ["Lethargy, sunken eyes", "Mild thirst", "Normal pulse", "Good skin turgor"],
    answer: "Lethargy, sunken eyes"
  },
  {
    question: "In children with ETEC, azithromycin is preferred over FQ due to:",
    options: ["Better taste", "Safety in pediatrics", "Cost", "IV route"],
    answer: "Safety in pediatrics"
  },
  {
    question: "Campylobacter resistance is increasing to:",
    options: ["Macrolides", "Fluoroquinolones", "Penicillins", "Cephalosporins"],
    answer: "Fluoroquinolones"
  },
  {
    question: "Non-typhoidal Salmonella treatment is indicated in:",
    options: ["All cases", "Systemic or high-risk patients", "Mild gastroenteritis", "Asymptomatic"],
    answer: "Systemic or high-risk patients"
  },
  {
    question: "Shigella treatment avoids antimotility drugs due to risk of:",
    options: ["HUS", "Toxic megacolon", "Neuropathy", "Hepatotoxicity"],
    answer: "Toxic megacolon"
  },

  // SECTION 2: Clostridioides difficile Infection (CDI) (40 questions)
  {
    question: "Non-severe CDI is defined by:",
    options: ["WBC >15 or SCR >1.5", "WBC ≤15 AND SCR ≤1.5 mg/dL", "Hypotension", "Ileus"],
    answer: "WBC ≤15 AND SCR ≤1.5 mg/dL"
  },
  {
    question: "Severe CDI includes:",
    options: ["WBC ≤15", "WBC >15 OR SCR >1.5 mg/dL", "Mild symptoms", "No fever"],
    answer: "WBC >15 OR SCR >1.5 mg/dL"
  },
  {
    question: "Fulminant CDI is characterized by:",
    options: ["Mild diarrhea", "Hypotension, shock, ileus, or megacolon", "WBC <10", "No treatment needed"],
    answer: "Hypotension, shock, ileus, or megacolon"
  },
  {
    question: "Preferred initial treatment for non-severe CDI:",
    options: ["Metronidazole", "Vancomycin 125 mg PO qid x 10 days or Fidaxomicin 200 mg PO bid x 10 days", "Rifaximin", "Fecal transplant"],
    answer: "Vancomycin 125 mg PO qid x 10 days or Fidaxomicin 200 mg PO bid x 10 days"
  },
  {
    question: "Alternative for non-severe CDI if vancomycin/fidaxomicin unavailable:",
    options: ["Vancomycin IV", "Metronidazole 500 mg PO q8h x 10 days", "Ciprofloxacin", "Doxycycline"],
    answer: "Metronidazole 500 mg PO q8h x 10 days"
  },
  {
    question: "For severe CDI, oral vancomycin is preferred because:",
    options: ["IV is better", "Must be oral; IV ineffective", "Cheap", "Once daily"],
    answer: "Must be oral; IV ineffective"
  },
  {
    question: "For fulminant CDI, vancomycin is given:",
    options: ["125 mg PO", "500 mg PO or NG q6h + Metronidazole 500 mg IV q8h", "IV only", "Rectal only"],
    answer: "500 mg PO or NG q6h + Metronidazole 500 mg IV q8h"
  },
  {
    question: "If ileus in fulminant CDI, vancomycin is administered:",
    options: ["Orally", "500 mg in 100 mL NS rectally q6h", "IV", "Subcutaneously"],
    answer: "500 mg in 100 mL NS rectally q6h"
  },
  {
    question: "Fulminant CDI may require:",
    options: ["Observation", "Surgery", "Probiotics", "Antidiarrheals"],
    answer: "Surgery"
  },
  {
    question: "For 1st recurrence of CDI, options include:",
    options: ["Metronidazole", "Fidaxomicin standard or extended regimen or Vancomycin pulse/taper", "Rifaximin only", "Surgery"],
    answer: "Fidaxomicin standard or extended regimen or Vancomycin pulse/taper"
  },
  {
    question: "For ≥2nd recurrence of CDI, what is recommended?",
    options: ["Vancomycin only", "Vancomycin → Rifaximin or FMT", "Metronidazole", "Bezlotoxumab alone"],
    answer: "Vancomycin → Rifaximin or FMT"
  },
  {
    question: "Bezlotoxumab (Zinplava) is given as:",
    options: ["10 mg/kg IV x 1 dose", "500 mg PO", "250 mg IM", "Daily for 10 days"],
    answer: "10 mg/kg IV x 1 dose"
  },
  {
    question: "Bezlotoxumab is used during active CDI therapy to:",
    options: ["Treat", "Prevent recurrence", "Cure", "Replace antibiotics"],
    answer: "Prevent recurrence"
  },
  {
    question: "Fecal microbiota transplant (FMT) is used in:",
    options: ["First episode", "≥2nd recurrence", "Non-severe", "Prophylaxis"],
    answer: "≥2nd recurrence"
  },
  {
    question: "What should be avoided in CDI as it may worsen symptoms?",
    options: ["Vancomycin", "Loperamide, bile-acid sequestrants", "Fidaxomicin", "Metronidazole"],
    answer: "Loperamide, bile-acid sequestrants"
  },
  {
    question: "CDI is caused by:",
    options: ["Gram-negative", "Spore-forming gram-positive anaerobic bacterium", "Virus", "Fungus"],
    answer: "Spore-forming gram-positive anaerobic bacterium"
  },
  {
    question: "CDI toxins are:",
    options: ["A and B", "Toxin A and B", "Only toxin A", "Only toxin B"],
    answer: "Toxin A and B"
  },
  {
    question: "Risk factors for CDI include:",
    options: ["Young age", "Antibiotic use, healthcare exposure, PPI", "Vaccination", "Exercise"],
    answer: "Antibiotic use, healthcare exposure, PPI"
  },
  {
    question: "Clinical presentation of CDI includes:",
    options: ["Watery diarrhea", "Watery diarrhea, abdominal pain, fever", "Constipation", "Rash"],
    answer: "Watery diarrhea, abdominal pain, fever"
  },
  {
    question: "Severe CDI may lead to:",
    options: ["Mild symptoms", "Toxic megacolon", "Recovery without treatment", "Viral superinfection"],
    answer: "Toxic megacolon"
  },
  {
    question: "Diagnostic test for CDI includes:",
    options: ["Blood culture", "Toxin EIA, GDH, NAAT", "Stool culture only", "Urine test"],
    answer: "Toxin EIA, GDH, NAAT"
  },
  {
    question: "Multi-step algorithm is used for CDI diagnosis to:",
    options: ["Confirm active infection", "Confirm active infection versus colonization", "Rule out viral", "Detect resistance"],
    answer: "Confirm active infection versus colonization"
  },
  {
    question: "Indications for oral vancomycin or fidaxomicin include:",
    options: ["All patients", "Non-severe cases", "Severe cases", "Mild only"],
    answer: "Non-severe cases"
  },
  {
    question: "Fulminant CDI requires:",
    options: ["Oral only", "IV metronidazole + rectal vancomycin", "Observation", "Probiotics"],
    answer: "IV metronidazole + rectal vancomycin"
  },
  {
    question: "Recurrence rate of CDI after first episode is:",
    options: ["5%", "20–30%", "50%", "80%"],
    answer: "20–30%"
  },
  {
    question: "Fidaxomicin has lower recurrence rate due to:",
    options: ["Narrow spectrum", "Spare normal flora", "IV route", "Once daily"],
    answer: "Spare normal flora"
  },
  {
    question: "Vancomycin taper/pulse is used for:",
    options: ["First episode", "Recurrence", "Prophylaxis", "Severe only"],
    answer: "Recurrence"
  },
  {
    question: "FMT restores:",
    options: ["Toxin production", "Normal gut microbiota", "Acid production", "Mucus layer"],
    answer: "Normal gut microbiota"
  },
  {
    question: "Bezlotoxumab is a:",
    options: ["Antibiotic", "Monoclonal antibody against toxin B", "Probiotic", "Antidiarrheal"],
    answer: "Monoclonal antibody against toxin B"
  },
  {
    question: "Antimotility agents worsen CDI by:",
    options: ["Reducing absorption", "Prolonging toxin exposure", "Increasing resistance", "Causing allergy"],
    answer: "Prolonging toxin exposure"
  },
  {
    question: "CDI spores are resistant to:",
    options: ["Alcohol", "Alcohol-based hand sanitizers", "Soap", "Bleach"],
    answer: "Alcohol-based hand sanitizers"
  },
  {
    question: "Prevention of CDI includes:",
    options: ["Antibiotic stewardship", "Antibiotic stewardship, hand hygiene, contact precautions", "Probiotics always", "Loperamide"],
    answer: "Antibiotic stewardship, hand hygiene, contact precautions"
  },
  {
    question: "Which antibiotic is least likely to cause CDI?",
    options: ["Clindamycin", "Fidaxomicin", "Ciprofloxacin", "Cephalexin"],
    answer: "Fidaxomicin"
  },
  {
    question: "CDI is a healthcare-associated infection strongly linked to:",
    options: ["Outpatient", "Prior antibiotic use", "Vaccination", "Diet"],
    answer: "Prior antibiotic use"
  },
  {
    question: "Toxin testing confirms:",
    options: ["Colonization", "Active infection", "Past infection", "Immunity"],
    answer: "Active infection"
  },
  {
    question: "NAAT detects:",
    options: ["Toxin", "TcdA/TcdB genes", "Spore", "Antibody"],
    answer: "TcdA/TcdB genes"
  },
  {
    question: "GDH test is a screening for:",
    options: ["Toxin", "C. difficile antigen", "Virus", "Parasite"],
    answer: "C. difficile antigen"
  },
  {
    question: "Vancomycin achieves high levels in:",
    options: ["Blood", "Gut lumen (oral)", "CSF", "Urine"],
    answer: "Gut lumen (oral)"
  },
  {
    question: "Fidaxomicin is bactericidal against:",
    options: ["All bacteria", "C. difficile with minimal flora disruption", "Gram-negatives", "Viruses"],
    answer: "C. difficile with minimal flora disruption"
  },

  // SECTION 3: Traveler's Diarrhea (30 questions)
  {
    question: "Most common cause of traveler's diarrhea (80%)?",
    options: ["Salmonella", "ETEC", "Norovirus", "Giardia"],
    answer: "ETEC"
  },
  {
    question: "Other common pathogens in traveler's diarrhea include:",
    options: ["Rotavirus", "Campylobacter, Shigella, Salmonella", "Vibrio", "E. coli O157"],
    answer: "Campylobacter, Shigella, Salmonella"
  },
  {
    question: "Prevention of traveler's diarrhea includes avoiding:",
    options: ["Bottled water", "Unpeeled fruits, raw veggies, tap water, ice", "Cooked food", "Sealed drinks"],
    answer: "Unpeeled fruits, raw veggies, tap water, ice"
  },
  {
    question: "For prophylaxis in high-risk travelers (up to 3 weeks), what is used?",
    options: ["Ciprofloxacin daily", "Bismuth subsalicylate 524 mg PO qid", "Loperamide", "Probiotics"],
    answer: "Bismuth subsalicylate 524 mg PO qid"
  },
  {
    question: "Antibiotic prophylaxis preferred for Southeast Asia?",
    options: ["Rifaximin", "Ciprofloxacin", "Azithromycin", "Doxycycline"],
    answer: "Ciprofloxacin"
  },
  {
    question: "Antibiotic prophylaxis for Latin America/Africa?",
    options: ["Ciprofloxacin", "Rifaximin", "Azithromycin", "Metronidazole"],
    answer: "Rifaximin"
  },
  {
    question: "For mild traveler's diarrhea, treatment is:",
    options: ["Antibiotics", "Supportive, fluids", "Loperamide only", "Hospitalization"],
    answer: "Supportive, fluids"
  },
  {
    question: "For moderate/severe traveler's diarrhea, fluoroquinolone is given for:",
    options: ["3–5 days", "1–3 days", "7 days", "Single dose only"],
    answer: "1–3 days"
  },
  {
    question: "Alternative to FQ in moderate/severe traveler's diarrhea?",
    options: ["Doxycycline", "Azithromycin 500 mg x 3 days", "Metronidazole", "Clindamycin"],
    answer: "Azithromycin 500 mg x 3 days"
  },
  {
    question: "Rifaximin is used in traveler's diarrhea when:",
    options: ["FQ resistance", "FQ resistance, pregnancy, child", "Bloody stool", "Fever"],
    answer: "FQ resistance, pregnancy, child"
  },
  {
    question: "Loperamide is avoided in traveler's diarrhea with:",
    options: ["Mild symptoms", "Bloody stool or fever", "No fever", "Children only"],
    answer: "Bloody stool or fever"
  },
  {
    question: "Loperamide OTC regimen:",
    options: ["2 mg daily", "4 mg initial + 2 mg after each stool (max 16 mg/day)", "1 mg bid", "8 mg once"],
    answer: "4 mg initial + 2 mg after each stool (max 16 mg/day)"
  },
  {
    question: "Stop loperamide if no improvement after:",
    options: ["24h", "48h", "72h", "1 week"],
    answer: "48h"
  },
  {
    question: "Epidemiology: Traveler's diarrhea affects:",
    options: ["<10%", "30–70% travelers to endemic regions", ">90%", "Only children"],
    answer: "30–70% travelers to endemic regions"
  },
  {
    question: "Most cases of traveler's diarrhea are:",
    options: ["Viral", "Bacterial (predominantly ETEC)", "Parasitic", "Fungal"],
    answer: "Bacterial (predominantly ETEC)"
  },
  {
    question: "Clinical presentation includes:",
    options: ["Constipation", "Sudden diarrhea with malaise, anorexia, abdominal cramps", "Rash", "Cough"],
    answer: "Sudden diarrhea with malaise, anorexia, abdominal cramps"
  },
  {
    question: "Nonpharmacologic prevention includes:",
    options: ["Eat street food", "Avoidance of risky food/drinks", "Drink tap water", "Share drinks"],
    answer: "Avoidance of risky food/drinks"
  },
  {
    question: "Pharmacologic prevention is:",
    options: ["Routine", "Bismuth subsalicylate (up to 3 weeks)", "Antibiotics always", "Probiotics"],
    answer: "Bismuth subsalicylate (up to 3 weeks)"
  },
  {
    question: "Antibiotics for prophylaxis are reserved for:",
    options: ["All", "High-risk or severe consequence cases", "Children", "Elderly only"],
    answer: "High-risk or severe consequence cases"
  },
  {
    question: "Treatment aims to reduce duration from:",
    options: ["1 day", "Several days to <1 day", "1 week", "No change"],
    answer: "Several days to <1 day"
  },
  {
    question: "Loperamide can be used for:",
    options: ["Bloody stool", "Symptomatic relief if no bloody stools or fever", "Fever", "Children <2"],
    answer: "Symptomatic relief if no bloody stools or fever"
  },
  {
    question: "Rifaximin is non-absorbed and acts:",
    options: ["Systemically", "Locally in gut", "IV", "Topically"],
    answer: "Locally in gut"
  },
  {
    question: "Azithromycin is preferred in:",
    options: ["FQ-resistant areas", "FQ-resistant areas, pregnancy, children", "All cases", "Prophylaxis"],
    answer: "FQ-resistant areas, pregnancy, children"
  },
  {
    question: "Bismuth subsalicylate mechanism:",
    options: ["Antibiotic", "Antisecretory, anti-inflammatory", "Antimotility", "Probiotic"],
    answer: "Antisecretory, anti-inflammatory"
  },
  {
    question: "Travelers should carry:",
    options: ["Nothing", "Loperamide + antibiotic", "IV fluids", "Surgery kit"],
    answer: "Loperamide + antibiotic"
  },
  {
    question: "Self-limiting means:",
    options: ["Needs antibiotics", "Usually resolves without treatment", "Chronic", "Requires admission"],
    answer: "Usually resolves without treatment"
  },
  {
    question: "High-risk destinations include:",
    options: ["USA", "Latin America, Africa, Asia", "Europe", "Canada"],
    answer: "Latin America, Africa, Asia"
  },
  {
    question: "Incubation period for ETEC is:",
    options: ["1–3 days", "1–3 days", "1 week", "1 month"],
    answer: "1–3 days"
  },
  {
    question: "Prophylaxis duration limit:",
    options: ["1 week", "Up to 3 weeks", "1 month", "Indefinite"],
    answer: "Up to 3 weeks"
  },
  {
    question: "Loperamide max daily dose:",
    options: ["8 mg", "16 mg", "32 mg", "4 mg"],
    answer: "16 mg"
  },

  // SECTION 4: Tuberculosis (TB) (40 questions)
  {
    question: "Causative agent of TB:",
    options: ["M. leprae", "Mycobacterium tuberculosis", "M. avium", "M. kansasii"],
    answer: "Mycobacterium tuberculosis"
  },
  {
    question: "TB is an:",
    options: ["Acid-fast aerobic bacillus", "Gram-negative", "Virus", "Fungus"],
    answer: "Acid-fast aerobic bacillus"
  },
  {
    question: "Latent TB is:",
    options: ["Contagious", "Asymptomatic, non-infectious", "Symptomatic", "Cavitary"],
    answer: "Asymptomatic, non-infectious"
  },
  {
    question: "Active TB presents with:",
    options: ["No symptoms", "Fever, cough, hemoptysis, night sweats", "Rash", "Joint pain"],
    answer: "Fever, cough, hemoptysis, night sweats"
  },
  {
    question: "Active TB is:",
    options: ["Non-contagious", "Contagious", "Only in children", "Self-limiting"],
    answer: "Contagious"
  },
  {
    question: "TST ≥5 mm is positive in:",
    options: ["Low-risk", "High-risk (HIV, close contact)", "All", "None"],
    answer: "High-risk (HIV, close contact)"
  },
  {
    question: "IGRA is preferred over TST in:",
    options: ["Children", "BCG-vaccinated", "Elderly", "Pregnant"],
    answer: "BCG-vaccinated"
  },
  {
    question: "CXR in active TB shows:",
    options: ["Normal", "Upper-lobe cavitary lesions", "Lower lobe", "Pleural effusion only"],
    answer: "Upper-lobe cavitary lesions"
  },
  {
    question: "Gold standard for active TB diagnosis:",
    options: ["TST", "Sputum smear for acid-fast bacilli", "IGRA", "CXR"],
    answer: "Sputum smear for acid-fast bacilli"
  },
  {
    question: "Rifampin (RIF) mechanism:",
    options: ["Inhibits mycolic acid", "Inhibits RNA polymerase", "Cell wall", "Protein synthesis"],
    answer: "Inhibits RNA polymerase"
  },
  {
    question: "Rifampin causes:",
    options: ["Orange fluids", "Orange fluids, CYP induction", "Neuropathy", "Vision loss"],
    answer: "Orange fluids, CYP induction"
  },
  {
    question: "Rifampin is hepatotoxic with:",
    options: ["PZA", "INH", "EMB", "All"],
    answer: "INH"
  },
  {
    question: "Isoniazid (INH) mechanism:",
    options: ["RNA", "Inhibits mycolic acid synthesis", "Arabinogalactan", "pH"],
    answer: "Inhibits mycolic acid synthesis"
  },
  {
    question: "INH is a prodrug activated by:",
    options: ["CYP", "KAT (katG)", "Liver", "Kidney"],
    answer: "KAT (katG)"
  },
  {
    question: "INH causes peripheral neuropathy prevented by:",
    options: ["Folic acid", "Pyridoxine 25–50 mg daily", "Vitamin C", "Calcium"],
    answer: "Pyridoxine 25–50 mg daily"
  },
  {
    question: "Pyrazinamide (PZA) mechanism:",
    options: ["RNA", "Lowers membrane potential (pH-activated in macrophages)", "Mycolic acid", "Vision"],
    answer: "Lowers membrane potential (pH-activated in macrophages)"
  },
  {
    question: "PZA causes:",
    options: ["Neuropathy", "Hepatotoxicity, hyperuricemia", "Orange urine", "Vision loss"],
    answer: "Hepatotoxicity, hyperuricemia"
  },
  {
    question: "Ethambutol (EMB) mechanism:",
    options: ["Mycolic acid", "Inhibits arabinogalactan synthesis", "RNA", "pH"],
    answer: "Inhibits arabinogalactan synthesis"
  },
  {
    question: "EMB causes:",
    options: ["Hepatotoxicity", "Optic neuritis (red/green vision loss)", "Orange fluids", "Neuropathy"],
    answer: "Optic neuritis (red/green vision loss)"
  },
  {
    question: "EMB requires:",
    options: ["Liver test", "Monitor visual acuity", "Renal", "Hearing"],
    answer: "Monitor visual acuity"
  },
  {
    question: "Intensive phase of TB treatment:",
    options: ["RIPE x 4 months", "RIPE x 2 months", "INH x 9 months", "RIF only"],
    answer: "RIPE x 2 months"
  },
  {
    question: "Continuation phase:",
    options: ["RIPE x 4 months", "RIF + INH x 4 months (total 6 mo)", "PZA only", "EMB only"],
    answer: "RIF + INH x 4 months (total 6 mo)"
  },
  {
    question: "Treatment extended to 9 months if:",
    options: ["No cavitation", "Cavitation or positive culture after 2 mo", "Latent", "MDR"],
    answer: "Cavitation or positive culture after 2 mo"
  },
  {
    question: "DOT is recommended to:",
    options: ["Reduce cost", "Ensure adherence", "Shorten duration", "Prevent resistance"],
    answer: "Ensure adherence"
  },
  {
    question: "Transmission of TB is via:",
    options: ["Food", "Airborne aerosolized droplets", "Water", "Blood"],
    answer: "Airborne aerosolized droplets"
  },
  {
    question: "LTBI treatment options include:",
    options: ["RIPE", "INH x 9 months or RIF x 4 months", "Antibiotics", "Surgery"],
    answer: "INH x 9 months or RIF x 4 months"
  },
  {
    question: "MDR-TB is resistant to:",
    options: ["INH only", "INH and RIF", "PZA", "EMB"],
    answer: "INH and RIF"
  },
  {
    question: "XDR-TB includes resistance to:",
    options: ["INH, RIF", "INH, RIF, FQ, injectable", "All drugs", "None"],
    answer: "INH, RIF, FQ, injectable"
  },
  {
    question: "RIPE stands for:",
    options: ["Rifampin, Isoniazid, Pyrazinamide, Ethambutol", "Rifampin, Isoniazid, Pyrazinamide, Ethambutol", "Rifampin, INH, PZA, EMB", "All above"],
    answer: "Rifampin, Isoniazid, Pyrazinamide, Ethambutol"
  },
  {
    question: "PZA is active in:",
    options: ["Neutral pH", "Acidic environment (macrophages)", "Alkaline", "Blood"],
    answer: "Acidic environment (macrophages)"
  },
  {
    question: "EMB is bacteriostatic and used to:",
    options: ["Prevent resistance", "Prevent INH resistance", "Kill bacilli", "Reduce duration"],
    answer: "Prevent INH resistance"
  },
  {
    question: "Rifampin induces:",
    options: ["CYP enzymes", "CYP enzymes (warfarin, OCPs)", "Inhibits", "No effect"],
    answer: "CYP enzymes (warfarin, OCPs)"
  },
  {
    question: "INH inhibits:",
    options: ["CYP", "No CYP effect", "Induces", "Inhibits"],
    answer: "No CYP effect"
  },
  {
    question: "PZA monitoring includes:",
    options: ["Vision", "LFTs, uric acid", "Renal", "Hearing"],
    answer: "LFTs, uric acid"
  },
  {
    question: "EMB dose is weight-based and adjusted for:",
    options: ["Renal", "Vision", "Liver", "Age"],
    answer: "Vision"
  },
  {
    question: "Treatment success requires:",
    options: ["1 month", "Adherence to full course", "Partial", "Prophylaxis"],
    answer: "Adherence to full course"
  },
  {
    question: "Sputum conversion at 2 months predicts:",
    options: ["Failure", "Treatment success", "Resistance", "Relapse"],
    answer: "Treatment success"
  },
  {
    question: "Isolation is until:",
    options: ["1 week", "3 negative smears", "Symptoms gone", "CXR clear"],
    answer: "3 negative smears"
  },
  {
    question: "BCG vaccine is used in:",
    options: ["USA", "High-burden countries", "Adults", "Treatment"],
    answer: "High-burden countries"
  },

  // SECTION 5: Urinary Tract Infections (UTI) (40 questions)
  {
    question: "Most common UTI pathogen (75–90%):",
    options: ["Staph", "E. coli", "Enterococcus", "Pseudomonas"],
    answer: "E. coli"
  },
  {
    question: "Other Gram-negative UTI pathogens include:",
    options: ["Staph saprophyticus", "Proteus, Klebsiella, Pseudomonas", "Enterococcus", "Strep"],
    answer: "Proteus, Klebsiella, Pseudomonas"
  },
  {
    question: "Gram-positive UTI pathogens:",
    options: ["E. coli", "Staph saprophyticus, Enterococcus faecalis", "Pseudomonas", "Klebsiella"],
    answer: "Staph saprophyticus, Enterococcus faecalis"
  },
  {
    question: "Uncomplicated cystitis treatment: Nitrofurantoin dose and duration:",
    options: ["100 mg bid x 3 days", "100 mg PO bid x 5 days", "50 mg qid", "200 mg daily"],
    answer: "100 mg PO bid x 5 days"
  },
  {
    question: "Nitrofurantoin is avoided if CrCl <:",
    options: ["30", "60 mL/min", "90", "120"],
    answer: "60 mL/min"
  },
  {
    question: "TMP-SMX for uncomplicated cystitis if E. coli resistance <20%:",
    options: ["160/800 mg bid x 5 days", "160/800 mg PO bid x 3 days", "Single dose", "7 days"],
    answer: "160/800 mg PO bid x 3 days"
  },
  {
    question: "Fosfomycin dose for uncomplicated cystitis:",
    options: ["3 g single dose", "3 g PO single dose", "1 g tid", "6 g daily"],
    answer: "3 g PO single dose"
  },
  {
    question: "Fosfomycin has long tissue half-life of:",
    options: ["1 day", "3 days", "1 week", "1 month"],
    answer: "3 days"
  },
  {
    question: "Complicated UTI (no sepsis) PO route duration for FQ:",
    options: ["3 days", "5–7 days", "10–14 days", "Single dose"],
    answer: "5–7 days"
  },
  {
    question: "Complicated UTI PO alternatives duration:",
    options: ["5–7 days", "7–14 days", "3 days", "Single"],
    answer: "7–14 days"
  },
  {
    question: "Complicated UTI IV options:",
    options: ["Nitrofurantoin", "Cefepime, Ceftriaxone, Piperacillin/Tazobactam, Carbapenems", "Fosfomycin", "TMP-SMX"],
    answer: "Cefepime, Ceftriaxone, Piperacillin/Tazobactam, Carbapenems"
  },
  {
    question: "Step-down in complicated UTI:",
    options: ["IV to PO", "IV to PO when improved", "PO only", "IV only"],
    answer: "IV to PO when improved"
  },
  {
    question: "In pregnancy, safe UTI antibiotics include:",
    options: ["Cipro", "Amoxicillin, Amox/Clav, Cephalexin, Gentamicin", "Doxy", "FQ"],
    answer: "Amoxicillin, Amox/Clav, Cephalexin, Gentamicin"
  },
  {
    question: "Avoid in pregnancy 3rd trimester:",
    options: ["Cephalexin", "Nitrofurantoin", "Amoxicillin", "Gentamicin"],
    answer: "Nitrofurantoin"
  },
  {
    question: "Avoid in pregnancy:",
    options: ["Amox/Clav", "TMP-SMX", "Cephalexin", "Gentamicin"],
    answer: "TMP-SMX"
  },
  {
    question: "Prostatitis or pyelonephritis duration with TMP-SMX:",
    options: ["3 days", "4–12 weeks", "7 days", "Single dose"],
    answer: "4–12 weeks"
  },
  {
    question: "Chronic prostatitis may require:",
    options: ["3 days", "6–12 weeks", "1 week", "Single dose"],
    answer: "6–12 weeks"
  },
  {
    question: "Asymptomatic bacteriuria is treated in:",
    options: ["All", "Pregnant or before urologic procedure", "Men only", "Children"],
    answer: "Pregnant or before urologic procedure"
  },
  {
    question: "Uncomplicated UTI is typically:",
    options: ["Pyelonephritis", "Cystitis in healthy female", "Prostatitis", "Complicated"],
    answer: "Cystitis in healthy female"
  },
  {
    question: "Complicated UTI includes:",
    options: ["Healthy female", "Underlying abnormalities, immunosuppression", "No symptoms", "Children"],
    answer: "Underlying abnormalities, immunosuppression"
  },
  {
    question: "Clinical presentation: Dysuria, frequency, urgency suggest:",
    options: ["Pyelonephritis", "Cystitis", "Prostatitis", "Vaginal"],
    answer: "Cystitis"
  },
  {
    question: "Fever, flank pain, CVAT suggest:",
    options: ["Cystitis", "Pyelonephritis", "Prostatitis", "Vaginal"],
    answer: "Pyelonephritis"
  },
  {
    question: "Diagnosis includes:",
    options: ["Urinalysis", "Urinalysis (nitrite, leukocyte esterase), urine culture", "Blood", "Stool"],
    answer: "Urinalysis (nitrite, leukocyte esterase), urine culture"
  },
  {
    question: "Treatment is fosfomycin single dose for:",
    options: ["Pyelonephritis", "Uncomplicated cystitis", "Complicated", "Pregnancy"],
    answer: "Uncomplicated cystitis"
  },
  {
    question: "Beta-lactam duration is longer due to:",
    options: ["Resistance", "Shorter duration", "Longer duration", "No culture"],
    answer: "Longer duration"
  },
  {
    question: "Catheter-associated UTI requires:",
    options: ["No treatment", "Antibiotic based on culture", "Prophylaxis", "Removal only"],
    answer: "Antibiotic based on culture"
  },
  {
    question: "Special populations include:",
    options: ["Healthy", "Children, pregnant, catheter", "Men", "Elderly"],
    answer: "Children, pregnant, catheter"
  },
  {
    question: "Recurrent UTIs require:",
    options: ["Same treatment", "Evaluation for prophylaxis", "Surgery", "No treatment"],
    answer: "Evaluation for prophylaxis"
  },
  {
    question: "Resistance to ESBL, AmpC, CRE complicates:",
    options: ["Simple cases", "Treatment approach", "Diagnosis", "Prevention"],
    answer: "Treatment approach"
  },
  {
    question: "IDSA guidelines should be consulted for:",
    options: ["All", "Newest recommendations", "Old", "Local only"],
    answer: "Newest recommendations"
  },
  {
    question: "Nitrofurantoin concentrates in:",
    options: ["Blood", "Urine", "CSF", "Tissue"],
    answer: "Urine"
  },
  {
    question: "Fosfomycin is active against:",
    options: ["Gram-positive only", "MDR organisms", "Virus", "Fungus"],
    answer: "MDR organisms"
  },
  {
    question: "TMP-SMX resistance is increasing in:",
    options: ["E. coli", "E. coli", "Staph", "Enterococcus"],
    answer: "E. coli"
  },
  {
    question: "FQ are reserved for:",
    options: ["First-line", "Complicated or resistance", "Pregnancy", "Children"],
    answer: "Complicated or resistance"
  },
  {
    question: "Gentamicin is used in pregnancy for:",
    options: ["First-line", "Complicated or resistant", "Cystitis", "Prophylaxis"],
    answer: "Complicated or resistant"
  },
  {
    question: "Pyelonephritis requires:",
    options: ["Oral only", "Initial IV then PO", "PO only", "No treatment"],
    answer: "Initial IV then PO"
  },
  {
    question: "Prostatitis penetration requires:",
    options: ["Nitrofurantoin", "FQ or TMP-SMX", "Cephalexin", "Fosfomycin"],
    answer: "FQ or TMP-SMX"
  },

  // SECTION 6: Sexually Transmitted Infections (STIs) (40 questions)
  {
    question: "Preferred treatment for Chlamydia trachomatis:",
    options: ["Ceftriaxone", "Doxycycline 100 mg PO bid x 7 days", "Metronidazole", "Penicillin"],
    answer: "Doxycycline 100 mg PO bid x 7 days"
  },
  {
    question: "Alternative for Chlamydia:",
    options: ["Doxy", "Azithromycin 1 g PO x 1", "Ceftriaxone", "Fluconazole"],
    answer: "Azithromycin 1 g PO x 1"
  },
  {
    question: "Treat partners in Chlamydia:",
    options: ["No", "Yes", "Only if symptomatic", "Only if pregnant"],
    answer: "Yes"
  },
  {
    question: "N. gonorrhoeae treatment:",
    options: ["Doxy", "Ceftriaxone 500 mg IM x 1", "Azithromycin", "Penicillin"],
    answer: "Ceftriaxone 500 mg IM x 1"
  },
  {
    question: "For gonorrhea if ≥150 kg:",
    options: ["500 mg", "1 g IM", "250 mg", "2 g"],
    answer: "1 g IM"
  },
  {
    question: "Add doxycycline in gonorrhea if:",
    options: ["Always", "Chlamydia not excluded", "Only if pregnant", "Only if child"],
    answer: "Chlamydia not excluded"
  },
  {
    question: "Mild/moderate PID treatment:",
    options: ["Ceftriaxone only", "Ceftriaxone 500 mg IM x 1 + Dyy 100 mg bid x 14 days + Metro 500 mg bid x 14 days", "Penicillin", "Fluconazole"],
    answer: "Ceftriaxone 500 mg IM x 1 + Dyy 100 mg bid x 14 days + Metro 500 mg bid x 14 days"
  },
  {
    question: "Severe PID initial therapy:",
    options: ["Oral", "Cefotetan IV or Cefoxitin IV + Doxy PO/IV", "Metronidazole", "Azithromycin"],
    answer: "Cefotetan IV or Cefoxitin IV + Doxy PO/IV"
  },
  {
    question: "PID total duration:",
    options: ["7 days", "14 days", "3 days", "Single dose"],
    answer: "14 days"
  },
  {
    question: "Primary/secondary syphilis treatment:",
    options: ["Doxy", "Benzathine Pen G 2.4 million U IM x 1", "Ceftriaxone", "Metro"],
    answer: "Benzathine Pen G 2.4 million U IM x 1"
  },
  {
    question: "Early latent syphilis:",
    options: ["Weekly x 3", "Same as primary/secondary", "IV", "Oral"],
    answer: "Same as primary/secondary"
  },
  {
    question: "Late latent/tertiary syphilis:",
    options: ["Single dose", "2.4 million U IM weekly x 3", "IV", "Doxy"],
    answer: "2.4 million U IM weekly x 3"
  },
  {
    question: "Neurosyphilis treatment:",
    options: ["Benzathine", "Aqueous Crystalline Pen G 18–24 million U/day IV x 10–14 days", "Doxy", "Ceftriaxone"],
    answer: "Aqueous Crystalline Pen G 18–24 million U/day IV x 10–14 days"
  },
  {
    question: "Female trichomoniasis:",
    options: ["Metro 2 g", "Metronidazole 500 mg bid x 7 days", "Clinda", "Fluconazole"],
    answer: "Metronidazole 500 mg bid x 7 days"
  },
  {
    question: "Male trichomoniasis:",
    options: ["500 mg bid x 7 days", "Metronidazole 2 g single dose", "Doxy", "Ceftriaxone"],
    answer: "Metronidazole 2 g single dose"
  },
  {
    question: "Treat sexual partners in trichomoniasis:",
    options: ["No", "Yes", "Only if symptomatic", "Only female"],
    answer: "Yes"
  },
  {
    question: "Bacterial vaginosis treatment:",
    options: ["Fluconazole", "Metronidazole 500 mg bid x 7 days or 0.75% gel x 5 days", "Doxy", "Pen G"],
    answer: "Metronidazole 500 mg bid x 7 days or 0.75% gel x 5 days"
  },
  {
    question: "Alternative for BV:",
    options: ["Metro", "Clindamycin 2% cream qHS x 7 days or 300 mg PO bid x 7 days", "Fluconazole", "Ceftriaxone"],
    answer: "Clindamycin 2% cream qHS x 7 days or 300 mg PO bid x 7 days"
  },
  {
    question: "Vulvovaginal candidiasis treatment:",
    options: ["Metro", "Fluconazole 150 mg PO x 1", "Doxy", "Ceftriaxone"],
    answer: "Fluconazole 150 mg PO x 1"
  },
  {
    question: "Repeat fluconazole if needed:",
    options: ["24h", "72h", "1 week", "Never"],
    answer: "72h"
  },
  {
    question: "Topical azoles for candidiasis:",
    options: ["Oral", "1–14 days", "Single dose", "IV"],
    answer: "1–14 days"
  },
  {
    question: "HPV vaccine Gardasil 9 for ages 11–12:",
    options: ["3 doses", "2 doses 0, 6–12 mo", "1 dose", "Annual"],
    answer: "2 doses 0, 6–12 mo"
  },
  {
    question: "Gardasil 9 for ≥15 yo:",
    options: ["2 doses", "3 doses 0, 1–2, 6 mo", "1 dose", "Booster"],
    answer: "3 doses 0, 1–2, 6 mo"
  },
  {
    question: "Chlamydia is caused by:",
    options: ["Virus", "Obligate intracellular bacterium", "Fungus", "Parasite"],
    answer: "Obligate intracellular bacterium"
  },
  {
    question: "Gonorrhea causes:",
    options: ["Discharge", "Purulent discharge", "Rash", "Fever only"],
    answer: "Purulent discharge"
  },
  {
    question: "PID complications include:",
    options: ["Infertility", "Infertility, ectopic, chronic pain", "Cancer", "Death"],
    answer: "Infertility, ectopic, chronic pain"
  },
  {
    question: "Syphilis primary stage:",
    options: ["Rash", "Chancre", "Gumma", "Neurosyphilis"],
    answer: "Chancre"
  },
  {
    question: "Syphilis secondary stage:",
    options: ["Chancre", "Rash, fever, lymphadenopathy", "Latent", "Tertiary"],
    answer: "Rash, fever, lymphadenopathy"
  },
  {
    question: "Trichomoniasis causes:",
    options: ["Discharge", "Frothy discharge, itching", "Ulcer", "Wart"],
    answer: "Frothy discharge, itching"
  },
  {
    question: "BV is characterized by:",
    options: ["Yeast", "Fishy odor, clue cells", "Ulcer", "Wart"],
    answer: "Fishy odor, clue cells"
  },
  {
    question: "Candidiasis causes:",
    options: ["Discharge", "Cottage cheese discharge, itching", "Ulcer", "Wart"],
    answer: "Cottage cheese discharge, itching"
  },
  {
    question: "HPV causes:",
    options: ["Discharge", "Warts, cancer", "Ulcer", "Rash"],
    answer: "Warts, cancer"
  },
  {
    question: "Prevention of STIs includes:",
    options: ["Abstinence", "Condoms, vaccination, partner treatment", "Antibiotics", "Surgery"],
    answer: "Condoms, vaccination, partner treatment"
  },
  {
    question: "High-risk groups for STIs:",
    options: ["Elderly", "Young adults, MSM, multiple partners", "Children", "Pregnant only"],
    answer: "Young adults, MSM, multiple partners"
  },
  {
    question: "Screening is recommended for:",
    options: ["All", "Sexually active <25, high-risk", "Only symptomatic", "Never"],
    answer: "Sexually active <25, high-risk"
  },
  {
    question: "Partner treatment prevents:",
    options: ["Cure", "Reinfection", "Resistance", "Cancer"],
    answer: "Reinfection"
  },
  {
    question: "Neurosyphilis requires:",
    options: ["IM", "IV penicillin", "Oral", "Doxy"],
    answer: "IV penicillin"
  },
  {
    question: "Doxycycline is contraindicated in:",
    options: ["Adults", "Pregnancy, children <8", "Men", "Elderly"],
    answer: "Pregnancy, children <8"
  },

  // SECTION 7: Intra-abdominal Infections (IAI) / Peritonitis (30 questions)
  {
    question: "Primary SBP is:",
    options: ["GI rupture", "No GI rupture (ascitic fluid in cirrhotics)", "Surgery", "Persistent"],
    answer: "No GI rupture (ascitic fluid in cirrhotics)"
  },
  {
    question: "Secondary IAI involves:",
    options: ["No source", "GI perforation or surgery", "Blood", "Lung"],
    answer: "GI perforation or surgery"
  },
  {
    question: "Tertiary IAI is:",
    options: ["Initial", "Persistent after therapy", "Mild", "Cured"],
    answer: "Persistent after therapy"
  },
  {
    question: "Common pathogens in primary SBP:",
    options: ["Anaerobes", "E. coli, Klebsiella, Streptococcus pneumoniae", "Enterococcus", "MDRO"],
    answer: "E. coli, Klebsiella, Streptococcus pneumoniae"
  },
  {
    question: "Secondary IAI pathogens:",
    options: ["Gram-positive only", "E. coli, Bacteroides, Enterococcus, Klebsiella", "Virus", "Fungus"],
    answer: "E. coli, Bacteroides, Enterococcus, Klebsiella"
  },
  {
    question: "Tertiary IAI involves:",
    options: ["Common", "MDRO", "E. coli", "Strep"],
    answer: "MDRO"
  },
  {
    question: "Three pillars of IAI treatment:",
    options: ["Rest", "Antibiotics + source control + fluids", "Surgery only", "Probiotics"],
    answer: "Antibiotics + source control + fluids"
  },
  {
    question: "Empiric coverage for SBP:",
    options: ["Carbapenem", "Cefotaxime 2 g IV q8h or Ceftriaxone 2 g daily", "Metro", "FQ"],
    answer: "Cefotaxime 2 g IV q8h or Ceftriaxone 2 g daily"
  },
  {
    question: "SBP treatment duration:",
    options: ["3 days", "5 days", "7–14 days", "Indefinite"],
    answer: "5 days"
  },
  {
    question: "Secondary peritonitis high-risk empiric:",
    options: ["Cefazolin", "Pip-Tazo 4.5 g IV q6h or Cefepime + Metro; Carbapenem", "Doxy", "Pen G"],
    answer: "Pip-Tazo 4.5 g IV q6h or Cefepime + Metro; Carbapenem"
  },
  {
    question: "If ESBL risk in secondary IAI:",
    options: ["Ceftriaxone", "Carbapenem", "Cipro", "Metro"],
    answer: "Carbapenem"
  },
  {
    question: "Duration of IAI treatment after source control:",
    options: ["10–14 days", "4–7 days", "Single dose", "Indefinite"],
    answer: "4–7 days"
  },
  {
    question: "Source control includes:",
    options: ["Antibiotics", "Surgery, drainage", "Fluids", "Probiotics"],
    answer: "Surgery, drainage"
  },
  {
    question: "Fluid resuscitation in IAI:",
    options: ["None", "Crystalloids", "Colloids only", "Blood"],
    answer: "Crystalloids"
  },
  {
    question: "SBP occurs in:",
    options: ["Healthy", "Cirrhosis with ascites", "Children", "Pregnant"],
    answer: "Cirrhosis with ascites"
  },
  {
    question: "Diagnosis of SBP:",
    options: ["Blood", "Ascitic fluid PMN >250", "Urine", "Stool"],
    answer: "Ascitic fluid PMN >250"
  },
  {
    question: "Secondary peritonitis requires:",
    options: ["Medical only", "Surgical intervention", "Observation", "Probiotics"],
    answer: "Surgical intervention"
  },
  {
    question: "Empiric coverage must include:",
    options: ["Gram-positive only", "Gram-negatives, anaerobes, Enterococcus", "Virus", "Fungus"],
    answer: "Gram-negatives, anaerobes, Enterococcus"
  },
  {
    question: "De-escalation based on:",
    options: ["Guess", "Culture results", "Symptoms", "Time"],
    answer: "Culture results"
  },
  {
    question: "Short duration (4–7 days) is sufficient if:",
    options: ["No control", "Adequate source control", "MDRO", "Recurrent"],
    answer: "Adequate source control"
  },
  {
    question: "Carbapenems are reserved for:",
    options: ["All", "ESBL, high-risk", "Mild", "SBP"],
    answer: "ESBL, high-risk"
  },
  {
    question: "Piperacillin-tazobactam covers:",
    options: ["Gram-positive", "Broad: Gram-neg, anaerobes, Pseudomonas", "Virus", "Fungus"],
    answer: "Broad: Gram-neg, anaerobes, Pseudomonas"
  },
  {
    question: "Cefepime + metronidazole covers:",
    options: ["Anaerobes only", "Gram-neg + anaerobes", "Pseudomonas", "Enterococcus"],
    answer: "Gram-neg + anaerobes"
  },
  {
    question: "Enterococcus coverage needed in:",
    options: ["SBP", "High-risk, healthcare-associated", "Community", "Mild"],
    answer: "High-risk, healthcare-associated"
  },
  {
    question: "MDRO in tertiary IAI requires:",
    options: ["Standard", "Specialist consultation", "Short course", "No treatment"],
    answer: "Specialist consultation"
  },
  {
    question: "Prophylaxis in surgery:",
    options: ["Always", "Perioperative", "Post-op", "None"],
    answer: "Perioperative"
  },
  {
    question: "IAI classification helps guide:",
    options: ["Diet", "Antibiotic choice and duration", "Rest", "Exercise"],
    answer: "Antibiotic choice and duration"
  },
  {
    question: "Failure to control source leads to:",
    options: ["Cure", "Persistent infection", "Short course", "De-escalation"],
    answer: "Persistent infection"
  },
  {
    question: "Resuscitation goal:",
    options: ["Hypotension", "Hemodynamic stability", "Fever", "Pain"],
    answer: "Hemodynamic stability"
  },
  {
    question: "Imaging in IAI:",
    options: ["None", "CT abdomen", "X-ray only", "MRI"],
    answer: "CT abdomen"
  }



      // Add more up to 253 — this is starter pack of 60+ real ones
    ].concat(Array(253 - 60).fill(null).map((_, i) => ({
      question: `Question ${i + 61} from Dr. Mariam’s lecture`,
      options: [`Option A`, `Option B`, `Option C`, `Correct Answer`],
      answer: `Correct Answer`
    }))); // Placeholder — replace with real Qs

    // State
    let currentIndex = 0;
    let score = 0;
    const userAnswers = Array(questions.length).fill(null);
    const isAnswered = Array(questions.length).fill(false);

    // Elements
    const examCard = document.getElementById('exam-card');
    const resultsCard = document.getElementById('results-card');
    const questionText = document.getElementById('question-text');
    const optionsContainer = document.getElementById('options-container');
    const progressText = document.getElementById('progress-text');
    const scoreText = document.getElementById('score-text');
    const prevBtn = document.getElementById('prev-btn');
    const nextBtn = document.getElementById('next-btn');
    const finalScore = document.getElementById('final-score');
    const answerKeyContent = document.getElementById('answer-key-content');
    const restartBtn = document.getElementById('restart-btn');

    function updateHeader() {
      progressText.textContent = `Question ${currentIndex + 1} of ${questions.length}`;
      scoreText.textContent = `Score: ${score}`;
    }

    function renderQuestion() {
      const q = questions[currentIndex];
      questionText.textContent = q.question;
      optionsContainer.innerHTML = '';

      q.options.forEach(opt => {
        const btn = document.createElement('button');
        btn.type = 'button';
        btn.textContent = opt;
        btn.className = 'option-btn w-full text-left p-4 border-2 border-gray-300 rounded-xl font-medium text-gray-700 bg-white focus:outline-none focus:ring-2 focus:ring-indigo-300';

        if (isAnswered[currentIndex]) {
          const correct = q.answer;
          if (opt === correct) {
            btn.classList.add('bg-green-100', 'border-green-500', 'text-green-800', 'font-bold');
          } else if (opt === userAnswers[currentIndex]) {
            btn.classList.add('bg-red-100', 'border-red-500', 'text-red-800', 'font-bold');
          }
          btn.disabled = true;
        } else {
          btn.addEventListener('click', () => {
            userAnswers[currentIndex] = opt;
            isAnswered[currentIndex] = true;
            if (opt === q.answer) score++;
            renderQuestion();
          });
        }
        optionsContainer.appendChild(btn);
      });

      prevBtn.disabled = currentIndex === 0;
      nextBtn.textContent = currentIndex === questions.length - 1 ? 'Finish' : 'Next';
      nextBtn.disabled = !isAnswered[currentIndex] && currentIndex !== questions.length - 1;
      updateHeader();
    }

    function showResults() {
      examCard.classList.add('hidden');
      resultsCard.classList.remove('hidden');
      finalScore.textContent = `${score} / ${questions.length}`;
      answerKeyContent.innerHTML = '';
      questions.forEach((q, i) => {
        const div = document.createElement('div');
        div.className = `p-3 rounded border ${userAnswers[i] === q.answer ? 'bg-green-50 border-green-400' : 'bg-red-50 border-red-400'}`;
        div.innerHTML = `<strong>Q${i+1}:</strong> ${q.question.slice(0,60)}...<br>
                         <span class="text-xs">You: ${userAnswers[i] || '—'} | Correct: ${q.answer}</span>`;
        answerKeyContent.appendChild(div);
      });
    }

    prevBtn.onclick = () => { if (currentIndex > 0) { currentIndex--; renderQuestion(); } };
    nextBtn.onclick = () => {
      if (currentIndex < questions.length - 1) {
        currentIndex++;
        renderQuestion();
      } else if (isAnswered[currentIndex]) {
        showResults();
      }
    };
    restartBtn.onclick = () => {
      currentIndex = 0; score = 0; userAnswers.fill(null); isAnswered.fill(false);
      resultsCard.classList.add('hidden'); examCard.classList.remove('hidden');
      renderQuestion();
    };

    // Start instantly
    renderQuestion();
  </script>
</body>
</html>